Table 2.
HPL bioactive factors | Reported biological effects | Experimental model | References | |
---|---|---|---|---|
Growth factors, cytokines | BDNF | Supports NSC proliferation, migration, and differentiation | Neuronal precursors | [75, 76] |
Favors synaptic plasticity and facilitates synapse maturation | Neuronal precursors | [77, 78] | ||
Supports hippocampal neurogenesis | In rodents | [79, 80] | ||
EGF | Induces NSC proliferation and migration | NSC culture | [81] | |
Supports cortical tissue regeneration and motor function recovery | In vivo stroke model | [82–84] | ||
FGF | Promotes proliferation and differentiation of NSCs | Cell culture and in vivo | [85] | |
Stimulates neurogenesis | Focal ischemia model in rats | [82, 86] | ||
Regulates Schwann cell proliferation, axonal growth, and remyelination | Nerve injury in mice | [87] | ||
GSN | Inhibits apoptosis and is neuroprotective in murine stroke | Hippocampal neuron culture, in vivo stroke model | [88, 89] | |
HGF | Protects dopaminergic neurons, motor neurons, and sympathetic neurons | Neuron culture | [90, 91] | |
IGF | Promotes NSC growth and differentiation, stimulates adult hippocampal neurogenesis, has neuroprotective activity | Neuronal cell culture, in vivo administration | [31, 92–95] | |
LGALS1 | Prevents microglial activation and promotes neuroprotection | Culture of microglia and astrocytes; in mice | [96, 97] | |
Promotes astrocyte maturation but inhibits proliferation | In vitro cell culture | [98] | ||
MANF | Protects rat embryonic nigral dopaminergic neurons | Rat model of PD | [99] | |
Is neuroprotective and neurorestorative | Rat model of PD | [100] | ||
Supports the development and sprouting of dopaminergic axonal terminals | In vitro cell culture | [99] | ||
Decreases stress and activates the PI3K/Akt/mTOR pathway | In vitro cell culture | [101] | ||
Activates the PI3K/Akt/GSK3β pathway and Nrf2 nuclear translocation | In vitro | [102] | ||
Inhibits apoptosis | In vitro cell culture | [103] | ||
Inhibits autophagic via activation of the AMPK/mTOR pathway and ameliorates ROS by maintaining mitochondrial function | In vitro cell culture | [104] | ||
NENF | Promotes neurotrophic activity and neuronal cell proliferation and stimulates differentiation | Mouse neural precursor cells | [105] | |
Is a novel player in the maintenance of the anxiety circuitry | Neudesin-null mice | [106] | ||
PDGF | Regulates NSC proliferation, migration, differentiation, and survival processes, and reduces apoptosis | Cultured NSCs | [107, 108] | |
Protects cells against MPP+-induced cell death | SH-SY5Y cell culture | [109] | ||
Has restorative effects | Rodent model of PD | [110, 111] | ||
PF4 | Promotes neuronal differentiation in DBA/2 mice | Mouse primary cells and in vivo infusion | [112] | |
TGF-β | Triggers differentiation of precursor cells | In vitro and in vivo mouse mesencephalic progenitors | [113] | |
VEGF | Promotes proliferation and migration of endothelial cells, and the formation of new blood vessels in vivo, and enhances vascular permeability | In vitro endothelial cell culture | [114] | |
Slows progression of amyotrophic lateral sclerosis in mice by stimulating motoneuron functions | Rat model of amyotrophic lateral sclerosis | [115, 116] | ||
Protects cultured motoneurons against death in conditions of hypoxia, oxidative stress, and serum deprivation | Neuronal cell culture | [117, 118] | ||
Exerts protective effects on primary hippocampal neurons against glutamate toxicity | In vitro neuronal culture | [119] | ||
Chemicals | Vit B12 | Prevents cognitive decline | Clinical trials | [120, 121] |
Serotonin | Modulates neural activity | Ex vivo using rat brains | [122] | |
Chemokines | RANTES | Can be neuroprotective | Primary cortical neuron culture, AD and stroke models | [123, 124] |
Contributes to neuronal synaptic activity and memory formation | Primary neuron culture and WT and CCL5-/- mice | [125, 126] | ||
Reduces neuronal degeneration and memory dysfunction after mTBI | Primary neuron culture, mTBI mouse model | [127] | ||
MIF | Mediates neuroprotective effects in Parkinson’s disease | Mouse model of PD, SH-SY5Y in vitro model of PD | [128] | |
Antioxidants | CAT | Protects against dopaminergic neuronal cell death | Mesencephalic neuronal–glial culture, rat stroke model | [129, 130] |
CP | Inhibits lipid peroxidation and ROS | CP−/− mouse model | [131] | |
Exerts protective activity against iron-induced oxidative damage in Alzheimer’s disease and TBIs | CP −/−, AD, focal cortical contusion injury mouse models | [131–133] | ||
GPX | Protects mammalian cells against oxidative damage | Human cell line cultures | [134] | |
Is protective in Huntington’s disease models (inhibits the activity of ROS-producing enzymes) | In vitro cell culture and Drosophila Huntington’s disease model | [135] | ||
SOD | Inhibits lipid peroxidation, is neuroprotective | In vitro primary cultured cortical neurons and rat stroke model | [130, 136, 137] | |
Trx (TXN) |
Protects against oxidative stress-associated diseases Modulates microtubule polymerization kinetics in vivo |
PC12 cell culture | [138, 139] | |
Is involved in cell–cell communication, transcriptional regulation, cell signaling, and DNA synthesis | Focal brain ischemia in rats | [140] | ||
Exerts a cytoprotective effect in the nervous system | RASMC and raw cell culture | [141] | ||
GCLM | Is associated with glutathione synthesis | In vivo | [142, 143] | |
Interleukins | TIMP-1 | Regulates neuroinflammation and neuropathic pain | In vivo in mice and rats | [144–147] |
Modulates astrocyte function and myelination | In vivo | [148, 149] | ||
IL-4 | Has anti-inflammatory properties | Human monocytes, murine bone marrow-derived macrophage culture | [150] | |
Platelet-EVs | GFs | Stimulates angiogenesis and neurogenesis | Rat ischemia model | [151] |
miR-126-3p | Exerts anti-inflammatory effects | Primary human macrophages | [152] |
AMPK Adenosine monophosphate-activated protein kinase, AD Alzheimer disease, BDNF brain-derived neurotrophic factor, CAT catalase, CCL5 CC chemokine ligand 5, CP ceruloplasmin, EGF epidermal growth factor, EV extracellular vesicle, FGF fibroblast growth factor, GAL-1 or LGALS1 galectin 1, gsn gelsolin, GCLM glutamate-cysteine ligase regulatory subunit, GPX glutathione peroxidase, GSK3β glycogen synthase kinase 3β, GF growth factor, HGF hepatocyte growth factor, IGF‐1 insulin‐like growth factor‐1, MANF mesencephalic astrocyte-derived neurotrophic factor, MIF macrophage migration inhibitory factor, mTOR mammalian target of rapamycin, mTBI mild traumatic brain injury, MPP myelin protein peripheral, NSC neural stem cell, NENF neuron-derived neurotrophic factor or neudesin, Nrf2 nuclear factor erythroid 2-related factor, PI3K phosphatidylinositol 3-kinase, PD Parkinson’s disease, PDGF platelet-derived growth factor, ROS reactive oxygen species, SOD superoxide dismutase, TIMP-1 tissue inhibitors of metalloproteinases 1, TXN thioredoxin, TGF-β transforming growth factor β, WT wild type